Crestline Management’s ResMed RMD Stock Holding History

Crestline Management’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,034	Closed	-$694K	–	518
2024 Q4	$694K	Buy	+3,034	New	+$731K	0.02%	482

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Crestline Management's RMD Position: Q1 2025 in Review

Crestline Management sold out of ResMed (RMD) in Q1 2025, closing a stake of 3,034 shares — an estimated $694K sold.

Crestline Management first reported a position in RMD in Q4 2024 and held it in 1 quarter. The position peaked at $694K in Q4 2024. 885 funds tracked by Wall St. Rank hold RMD as of Q1 2025.

Crestline Management reported no remaining ResMed position as of Q1 2025 after selling out during the quarter.
Crestline Management sold 3,034 ResMed shares in Q1 2025, an estimated $694K.
Crestline Management first reported a position in ResMed in Q4 2024 and held it in 1 quarter.
Crestline Management's ResMed position peaked at $694K in Q4 2024.
885 funds tracked by Wall St. Rank held ResMed as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.